-+ 0.00%
-+ 0.00%
-+ 0.00%

LifeSci Capital Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $4

Benzinga·12/22/2025 15:15:56
语音播报
LifeSci Capital initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $4.